UroGen Pharma Ltd (URGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.28B
Last updated: Nov 17, 2026 at 11:05 AM ET
UroGen Pharma Ltd (URGN) Stock Forecast
Analysts expect UroGen Pharma (URGN) to earn -$0.30 per share in the fiscal year ending Dec 31, 2026, on revenue of $319.58M. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 67.3%.
- Fiscal year ending Dec 31, 2026
- -$0.30
- EPS consensus, revenue $319.58M
- Fiscal year ending Dec 31, 2027
- $2.56
- EPS consensus, revenue $534.79M
- Next report
- Mar 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.30 | -$0.64 to -$0.11 | 6 | $319.58M | $307.56M to $326.40M | 7 |
| Dec 31, 2027 | $2.56 | $1.05 to $4.64 | 7 | $534.79M | $453.90M to $633.30M | 7 |
Quarterly Estimates
The EPS consensus falls from $0.46 for the quarter ending Dec 31, 2026 to $0.32 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.46 | $0.13 to $0.69 | 9 | $109.24M | $93.24M to $119.70M | 9 |
| Mar 31, 2027 | $0.32 | $0.01 to $0.68 | 5 | $114.50M | $103.50M to $128.70M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.24.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.30 | -$0.22 | -$0.24 | -$0.24 | -$0.24 | N/A |
| Fiscal year ending Dec 31, 2027 | $2.56 | $2.69 | $2.79 | $2.79 | $2.79 | -8.3% |
| Quarter ending Mar 31, 2027 | $0.32 | $0.39 | $0.42 | $0.42 | $0.42 | -23.6% |
Frequently Asked Questions About URGN
What is the URGN stock forecast?
Consensus analyst estimates put UroGen Pharma's EPS at -$0.30 for the fiscal year ending Dec 31, 2026, on revenue of $319.58M. The consensus rating from 7 analysts is Buy.
How do analysts rate URGN stock?
Of 7 analysts covering UroGen Pharma, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from URGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.30, with estimates from -$0.64 to -$0.11 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.56, with estimates from $1.05 to $4.64 from 7 analysts.
What revenue do analysts expect from UroGen Pharma next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $319.58M, with estimates from $307.56M to $326.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $534.79M, with estimates from $453.90M to $633.30M.
How many analysts cover URGN?
7 analysts rate UroGen Pharma stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
URGN pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts